drugset / Trial / NCT02055690
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
Phase 1/2
Terminated
21 enrolled
The Christie NHS Foundation Trust
East and North Hertfordshire NHS Trust · collabMateon Therapeutics · collabNovartis · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The first part of this study is to find the recommended dosages of a combination of two drugs: pazopanib and fosbretabulin, which will be given to female patients with relapsed ovarian cancer. The second part of the study involves comparing the recommended dose of pazopanib and fosbretabulin in combination against pazopanib alone in female patients with relapsed ovarian cancer to determine whether the combination is more beneficial that pazopanib on it's own.
Timeline
- Start
- 2014-09
- Primary completion
- 2017-11-24
- Completion
- 2017-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | 600 mg | Oral |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |
| Subject | fosbretabulin | Small molecule | 45 mg/m2 | Other |
| Subject | fosbretabulin | Small molecule | 54 mg/m2 | Other |
| Subject | fosbretabulin | Small molecule | 60 mg/m2 | Other |